Skip to main content
SpringerLink
Log in
Book cover

Cardiovascular Risk Assessment in Primary Prevention pp 35–58Cite as

European Guidelines for Risk Assessment in the Primary Prevention of Cardiovascular Disease

  • Chapter
  • First Online:

  • 885 Accesses

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

In this chapter, we summarize current recommendations from the European Society of Cardiology (ESC) for risk assessment in the primary prevention of cardiovascular disease (CVD). These risk assessment recommendations are drawn from the 2021 ESC guidelines on cardiovascular disease prevention. One of the most notable updates found in the 2021 ESC guidelines is the introduction of a new 10-year risk estimator (called SCORE2), which provides prognostic information on fatal and nonfatal CVD. The previous ESC-SCORE calculator only estimated 10-year risk for fatal CVD. Additional new recommendations include: (1) a novel two-step approach to personalizing risk factor targets, (2) the endorsement of bespoke risk calculators for older persons (SCORE2-OP), diabetics, and secondary prevention adults; (3) the introduction of lifetime treatment benefit estimates to inform prevention treatment decisions in the young (<50 years) and old (>70 years); (4) earlier commencement of pharmacotherapy in hypertensive patients; (5) more intensive targets in the reduction of LDL-C among select individuals, and (6) the recognition of new randomized controlled trial data supporting the use of SGLT2 inhibitors and GLP1-receptor agonists in patients with type 2 diabetes mellitus.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  • Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res. 2013;72:35–44.

    Article  CAS  PubMed  Google Scholar 

  • Berkelmans GF, Gudbjörnsdottir S, Visseren FL, Wild SH, Franzen S, Chalmers J, et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. Eur Heart J. 2019;40(34):2899–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–9.

    Article  CAS  PubMed  Google Scholar 

  • Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156(9):871–81.

    Article  PubMed  Google Scholar 

  • Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–8.

    Article  PubMed  Google Scholar 

  • Collaboration ERF. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22(12):839–69.

    Article  Google Scholar 

  • Conroy RM, Pyörälä K, Ae F, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.

    Article  CAS  PubMed  Google Scholar 

  • Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323.

    Article  PubMed  Google Scholar 

  • Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99(12):866–72.

    Article  PubMed  Google Scholar 

  • Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124–31.

    Article  CAS  PubMed  Google Scholar 

  • Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.

    Article  PubMed  Google Scholar 

  • Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407.

    Article  PubMed  CAS  Google Scholar 

  • Flather M. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

    Article  CAS  Google Scholar 

  • Force ESCPT. 2021 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021.

    Google Scholar 

  • Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.

    Article  PubMed  Google Scholar 

  • Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Part B):2935–59.

    Article  PubMed  Google Scholar 

  • Group ASC. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.

    Article  Google Scholar 

  • Group SR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  CAS  Google Scholar 

  • Group UPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65.

    Article  Google Scholar 

  • Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Gulsin GS, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70(5):1042–8.

    Article  CAS  PubMed  Google Scholar 

  • Hageman S PL, Kaptoge S, de Vries T, Xu Z, Chung R, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54.

    Google Scholar 

  • Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

    Article  CAS  PubMed  Google Scholar 

  • Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36.

    Article  PubMed  PubMed Central  Google Scholar 

  • Herrington W, Emberson J, Mihaylova B, Blackwell L, Reith C, Haynes R, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4(10):829.

    Article  PubMed  CAS  Google Scholar 

  • Jaspers NE, Blaha MJ, Matsushita K, Van Der Schouw YT, Wareham NJ, Khaw K-T, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2020;41(11):1190–9.

    Article  CAS  PubMed  Google Scholar 

  • Kaasenbrood L, Bhatt DL, Dorresteijn JA, Wilson PW, D'Agostino RB Sr, Massaro JM, et al. Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease: the SMART-REACH model. J Am Heart Assoc. 2018;7(16):e009217.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011;18(3):393–8.

    Article  PubMed  Google Scholar 

  • Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.

    Article  CAS  PubMed  Google Scholar 

  • Leitsalu L, Haller T, Esko T, Tammesoo M-L, Alavere H, Snieder H, et al. Cohort profile: Estonian biobank of the Estonian genome center, university of Tartu. Int J Epidemiol. 2015;44(4):1137–47.

    Article  PubMed  Google Scholar 

  • MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc. 2017;6(11):e006986.

    Article  PubMed  PubMed Central  Google Scholar 

  • Martin SS, Sperling LS, Blaha MJ, Wilson PW, Gluckman TJ, Blumenthal RS, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65(13):1361–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mora S, Wenger NK, Cook NR, Liu J, Howard BV, Limacher MC, et al. Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the Women’s Health Initiative. JAMA Intern Med. 2018;178(9):1231–40.

    Article  PubMed  PubMed Central  Google Scholar 

  • Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292(19):2343–9.

    Article  CAS  PubMed  Google Scholar 

  • Ollier W, Sprosen T, Peakman T. UK Biobank: from concept to reality. Pharmacogenomics. 2005;6(6):639–46.

    Google Scholar 

  • Patel A, Group AC. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.

    Article  CAS  PubMed  Google Scholar 

  • Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas A, et al. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. BMC Public Health. 2006;6(1):255. https://doi.org/10.1186/1471-2458-6-255.

  • Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

    Article  CAS  PubMed  Google Scholar 

  • Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone G, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging. 2017;18(9):945–60.

    Article  PubMed  Google Scholar 

  • Petrie JR, Chaturvedi N, Ford I, Brouwers MC, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597–609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A. European Guidelines on CVD prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on CVD Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.

    Article  PubMed  PubMed Central  Google Scholar 

  • Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994;110(2):121–61.

    Article  PubMed  Google Scholar 

  • Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654–61.

    Article  CAS  PubMed  Google Scholar 

  • Ricci C, Wood A, Muller D, Gunter MJ, Agudo A, Boeing H, et al. Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study. BMJ. 2018;361:k934.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sabanayagam C, Ezzati M, Rao KM, Khalili D, Lehtimaki T, Hajifathalian K, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–30.

    Article  Google Scholar 

  • Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(9):1768–74.

    Article  CAS  PubMed  Google Scholar 

  • SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455–67. https://doi.org/10.1093/eurheartj/ehab312.

  • Schmermund A, Möhlenkamp S, Stang A, Grönemeyer D, Seibel R, Hirche H, et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Am Heart J. 2002;144(2):212–8.

    Article  PubMed  Google Scholar 

  • Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Petersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010;31(7):883–91.

    Article  PubMed  Google Scholar 

  • Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–31.

    Article  CAS  PubMed  Google Scholar 

  • Simons PCG, Algra A, Van De Laak M, Grobbee D, Van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999;15(9):773–81.

    Article  CAS  PubMed  Google Scholar 

  • Sundström J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162(3):184–91.

    Article  PubMed  Google Scholar 

  • Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–37.

    Google Scholar 

  • Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.

    Article  PubMed  Google Scholar 

  • Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    Article  CAS  PubMed  Google Scholar 

  • Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged≥ 75 years: a randomized clinical trial. JAMA. 2016;315(24):2673–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.

    Article  CAS  PubMed  Google Scholar 

  • Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital Galway and SAOLTA University Health Care Group, Galway, Ireland

    Christian Cawley & John W. McEvoy

  2. National University of Ireland Galway, Galway, Ireland

    Christian Cawley

  3. National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway, Galway, Ireland

    John W. McEvoy

Authors
  1. Christian Cawley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. McEvoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John W. McEvoy .

Editor information

Editors and Affiliations

  1. Section on Cardiovascular Disease, Wake Forest University School of Medicine, Winston Salem, NC, USA

    Michael D. Shapiro

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cawley, C., McEvoy, J.W. (2022). European Guidelines for Risk Assessment in the Primary Prevention of Cardiovascular Disease. In: Shapiro, M.D. (eds) Cardiovascular Risk Assessment in Primary Prevention. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-98824-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98824-1_3

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-98823-4

  • Online ISBN: 978-3-030-98824-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation